UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-55
SponsorUkko Inc
About this trial
This study will test a new investigational treatment called UKK-0018. UKK-0018 as an immunotherapeutic for the treatment of peanut allergies. The treatment is given by injection and is designed to train the immune system to tolerate peanut exposure over time.
Eligibility criteria
Qualifiers
Adults 18-55 years old
documented history of physician-diagnosed peanut allergy
positive skin prick test (SPT)
screening DBPCFC peanut protein
Disqualifiers
asthma based on NHLBI
uncontrolled cardiovascular disease
chronic disease history
exacerbation of dermatological conditions
Trial design
Treatments tested in this trial
- UKK-0018
Treatment groups
40 Participants
are divided into 1 treatment groupLocations
5Australia
Royal Prince Alfred Hospital2050, CamperdownNew South Wales, Australia
Flinders Medical Center5042, Bedford ParkSouth Australia, Australia
The Royal Melbourne Hospital3065, FitzroyVictoria, Australia
Fiona Stanley Hospital6150, PerthWestern Australia, Australia
Sponsors and collaborators
Ukko Inc
Lead sponsor
Source ClinicalTrials.gov